Cellular, pharmacological, and biophysical evaluation of explanted lungs from a patient with sickle cell disease and severe pulmonary arterial hypertension

Pulmonary Circulation

Volumn 3, Issue 4, 2013, Pages 936-951

  Rogers, Natasha M ^a   Yao, Mingyi ^a   Sembrat, John ^a   George, M Patricia ^a   Knupp, Heather ^a   Ross, Mark ^a   Sharifi Sanjani, Maryam ^a   Milosevic, Jadranka ^b   Croix, Claudette St ^a   Rajkumar, Revathi ^a   Frid, Maria G ^c   Hunter, Kendall S ^c,d   Mazzaro, Luciano ^d   Novelli, Enrico M ^a   Stenmark, Kurt R ^c   Gladwin, Mark T ^a   Ahmad, Ferhaan ^a   Champion, Hunter C ^a   Isenberg, Jeffrey S ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d The University of Colorado Denver   (United States)

Author keywords

CD47; Endothelin 1; Lung transplant; Matrix; Pulmonary arterial hypertension; Sickle cell disease; Superoxide; Thrombospondin 1

Indexed keywords

EID: 84924245104     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.1086/674754     Document Type: Article

References (71)

1. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet 2010;376:2018–2031.
2. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl J Med 2000;342:1855–1865.
3. Abbott KC, Hypolite IO, Agodoa LY. Sickle cell nephropathy at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol 2002;58:9–15.
4. Aguilar C, Vichinsky E, Neumayr L. Bone and joint disease in sickle cell disease. Hematol Oncol Clin North Am 2005; 19:929–941, viii.
5. Mehta SH, Adams RJ. Treatment and prevention of stroke in children with sickle cell disease. Curr Treat Options Neurol 2006;8:503–512.
6. Graham JK, Mosunjac M, Hanzlick RL, Mosunjac M. Sickle cell lung disease and sudden death: a retrospective/ prospective study of 21 autopsy cases and literature review. Am J Forensic Med Pathol 2007;28:168–172.
7. Haque AK, Gokhale S, Rampy BA, Adegboyega P, Duarte A, Saldana MJ. Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. Hum Pathol 2002;33:1037–1043.
8. Fonseca GH, Souza R, Salemi VM, Jardim CV, Gualandro SF. Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. Eur Respir J 2012;39:112–118.
9. Mehari A, Alam S, Tian X, et al. Hemodynamic predictors of mortality in adults with sickle cell disease. Am J Respir Crit Care Med 2013;187:840–847.
10. Mehari A, Gladwin MT, Tian X, Machado RF, Kato GJ. Mortality in adults with sickle cell disease and pulmonary hypertension. JAMA 2012;307:1254–1256.
11. Parent F, Bachir D, Inamo J, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med 2011;365:44–53.
12. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004;350:886–895.
13. Ataga KI, Moore CG, Jones S, et al. Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br J Haematol 2006;134:109–115.
14. Machado RF, Barst RJ, Yovetich NA, et al. Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood 2011;118:855–864.
15. Nouraie M, Lee JS, Zhang Y, et al. The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica 2013;98:464–472.
16. Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002;8:1383–1389.
17. Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 2005; 294:81–90.
18. Aslan M, Ryan TM, Adler B, et al. Oxygen radical inhibition of nitric oxide–dependent vascular function in sickle cell disease. Proc Natl Acad Sci USA 2001;98:15215–15220.
19. Hsu LL, Champion HC, Campbell-Lee SA, et al. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood 2007;109:3088–3098.
20. De Franceschi L, Platt OS, Malpeli G, et al. Protective effects of phosphodiesterase-4 (PDE-4) inhibition in the early phase of pulmonary arterial hypertension in transgenic sickle cell mice. FASEB J 2008;22:1849–1860.
21. Kaul DK, Nagel RL, Chen D, Tsai HM. Sickle erythrocyteendothelial interactions in microcirculation: the role of von Willebrand factor and implications for vasoocclusion. Blood 1993;81:2429–2438.
22. Aslan M, Ryan TM, Townes TM, et al. Nitric oxide–dependent generation of reactive species in sickle cell disease: actin tyrosine induces defective cytoskeletal polymerization. J Biol Chem 2003;278:4194–4204.
23. Isenberg JS, Ridnour LA, Perruccio EM, Espey MG, Wink DA, Roberts DD. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci USA 2005;102:13141–13146.
24. Isenberg JS, Ridnour LA, Dimitry J, Frazier WA, Wink DA, Roberts DD. CD47 is necessary for inhibition of nitric oxide–stimulated vascular cell responses by thrombospondin-1. J Biol Chem 2006;281:26069–26080.
25. Bauer PM, Bauer EM, Rogers NM, et al. Activated CD47 promotes pulmonary arterial hypertension through targeting caveolin-1. Cardiovasc Res 2012;93:682–693.
26. Novelli EM, Kato GJ, Ragni MV, et al. Plasma thrombospondin-1 is increased during acute sickle cell vaso-occlusive events and associated with acute chest syndrome, hydroxyurea therapy, and lower hemolytic rates. Am J Hematol 2012;87: 326–330.
27. Lammers SR, Kao PH, Qi HJ, et al. Changes in the structure-function relationship of elastin and its impact on the proximal pulmonary arterial mechanics of hypertensive calves. Am J Physiol Heart Circ Physiol 2008;295:H1451–H1459.
28. Rajkumar R, Konishi K, Richards TJ, et al. Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension. Am J Physiol Heart Circ Physiol 2010;298:H1235–H1248.
29. Papierniak ES, Lowenthal DT, Mubarak K. Pulmonary arterial hypertension: classification and therapy with a focus on prostaglandin analogs. Am J Ther 2012;19:300–314.
30. Galiè N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004;61: 227–237.
31. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 2012;122:4306–4313.
32. Yu J, Taylor L, Wilson J, Comhair S, Erzurum S, Polgar P. Altered expression and signal transduction of endothelin-1 receptors in heritable and idiopathic pulmonary arterial hypertension. J Cell Physiol 2013;228:322–329.
33. Humbert M, Montani D, Perros F, Dorfmüller P, Adnot S, Eddahibi S. Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension. Vascul Pharmacol 2008;49: 113–118.
34. Isenberg JS, Annis DS, Pendrak ML, et al. Differential interactions of thrombospondin-1, -2, and -4 with CD47 and effects on cGMP signaling and ischemic injury responses. J Biol Chem 2009;284:1116–1125.
35. Dorfmüller P, Humbert M, Capron F, Muller KM. Pathology and aspects of pathogenesis in pulmonary arterial hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2003;20:9–19.
36. Griffith SL, Rhoades RA, Packer CS. Pulmonary arterial smooth muscle contractility in hypoxia-induced pulmonary hypertension. J Appl Physiol 1994;77:406–414.
37. Isenberg JS, Frazier WA, Roberts DD. Thrombospondin-1: a physiological regulator of nitric oxide signaling. Cell Mol Life Sci 2008;65:728–742.
38. Ochoa CD, Yu L, Al-Ansari E, Hales CA, Quinn DA. Thrombospondin-1 null mice are resistant to hypoxiainduced pulmonary hypertension. J Cardiothorac Surg 2010; 5:32.
39. Soto-Pantoja DR, Stein EV, Rogers NM, Sharifi-Sanjani M, Isenberg JS, Roberts DD. Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD 47. Expert Opin Ther Targets 2013;17:89–103.
40. Medhora M, Bousamra M 2nd, Zhu D, Somberg L, Jacobs ER. Upregulation of collagens detected by gene array in a model of flow-induced pulmonary vascular remodeling. Am J Physiol Heart Circ Physiol 2002;282:H414–H422.
41. Coflesky JT, Jones RC, Reid LM, Evans JN. Mechanical properties and structure of isolated pulmonary arteries remodeled by chronic hyperoxia. Am Rev Respir Dis 1987;136: 388–394.
42. Zuckerbraun BS, George P, Gladwin MT. Nitrite in pulmonary arterial hypertension: therapeutic avenues in the setting of dysregulated arginine/nitric oxide synthase signalling. Cardiovasc Res 2011;89:542–552.
43. Ignarro LJ. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J Physiol Pharmacol 2002;53:503–514.
44. Squadrito GL, Pryor WA. The formation of peroxynitrite in vivo from nitric oxide and superoxide. Chem Biol Interact 1995;96:203–206.
45. Drose S, Brandt U. Molecular mechanisms of superoxide production by the mitochondrial respiratory chain. Adv Exp Med Biol 2012;748:145–169.
46. Katsuyama M, Matsuno K, Yabe-Nishimura C. Physiological roles of NOX/NADPH oxidase, the superoxide-generating enzyme. J Clin Biochem Nutr 2012;50:9–22.
47. Vasquez-Vivar J, Kalyanaraman B, Martasek P. The role of tetrahydrobiopterin in superoxide generation from eNOS: enzymology and physiological implications. Free Radic Res 2003;37:121–127.
48. Dias-Da-Motta P, Arruda VR, Muscara MN, et al. The release of nitric oxide and superoxide anion by neutrophils and mononuclear cells from patients with sickle cell anaemia. Br J Haematol 1996;93:333–340.
49. Almeida CB, Franco-Penteado C, Saad ST, Costa FF, Conran N. Sickle cell disease serum induces NADPH enzyme subunit expression and oxidant production in leukocytes. Hematology 2010;15:422–429.
50. Greenacre SA, Ischiropoulos H. Tyrosine nitration: localisation, quantification, consequences for protein function and signal transduction. Free Radic Res 2001;34:541–581.
51. Morrell NW, Adnot S, Archer SL, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:S20–S31.
52. Crosswhite P, Sun Z. Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension. J Hypertens 2010;28:201–212.
53. Grunig E, Dehnert C, Mereles D, et al. Enhanced hypoxic pulmonary vasoconstriction in families of adults or children with idiopathic pulmonary arterial hypertension. Chest 2005; 128:630S–633S.
54. Niu X, Nouraie M, Campbell A, et al. Angiogenic and inflammatory markers of cardiopulmonary changes in children and adolescents with sickle cell disease. PloS ONE 2009; 4:e7956.
55. Mestre B, Pitie M, Loup C, Claparols C, Pratviel G, Meunier B. Influence of the nature of the porphyrin ligand on the nuclease activity of metalloporphyrin-oligonucleotide conjugates designed with cationic, hydrophobic or anionic metalloporphyrins. Nucleic Acids Res 1997;25:1022–1027.
56. Klings ES, Anton Bland D, Rosenman D, et al. Pulmonary arterial hypertension and left-sided heart disease in sickle cell disease: clinical characteristics and association with soluble adhesion molecule expression. Am J Hematol 2008; 83:547–553.
57. Anjum F, Lazar J, Zein J, Jamaleddine G, Demetis S, Wadgaonkar R. Characterization of altered patterns of endothelial progenitor cells in sickle cell disease related pulmonary arterial hypertension. Pulm Circ 2012;2:54–60.
58. Linguraru MG, Pura JA, Van Uitert RL, et al. Segmentation and quantification of pulmonary artery for noninvasive CT assessment of sickle cell secondary pulmonary hypertension. Med Phys 2010;37:1522–1532.
59. Sachdev V, Kato GJ, Gibbs JS, et al. Echocardiographic markers of elevated pulmonary pressure and left ventricular diastolic dysfunction are associated with exercise intolerance in adults and adolescents with homozygous sickle cell anemia in the United States and United Kingdom. Circulation 2011;124:1452–1460.
60. Anthi A, Machado RF, Jison ML, et al. Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med 2007;175:1272–1279.
61. George MP, Novelli EM, Shigemura N, et al. First successful lung transplantation for sickle cell disease with severe pulmonary arterial hypertension and pulmonary veno-occlusive disease. Pulm Circ 2013;3:952–958 (in this issue).
62. Phelan M, Perrine SP, Brauer M, Faller DV. Sickle erythrocytes, after sickling, regulate the expression of the endothelin-1 gene and protein in human endothelial cells in culture. J Clin Invest 1995;96:1145–1151.
63. Rybicki AC, Benjamin LJ. Increased levels of endothelin-1 in plasma of sickle cell anemia patients. Blood 1998;92:2594–2596.
64. Ergul S, Brunson CY, Hutchinson J, et al. Vasoactive factors in sickle cell disease: in vitro evidence for endothelin- 1-mediated vasoconstriction. Am J Hematol 2004;76:245–251.
65. Frantz C. Role of thrombospondin-1 in pulmonary hypertension: a proof of concept [dissertation]. Universität des Saarlandes, 2011.
66. Estrada KD, Chesler NC. Collagen-related gene and protein expression changes in the lung in response to chronic hypoxia. Biomech Model Mechanobiol 2009;8:263–272.
67. Berg JT, Breen EC, Fu Z, Mathieu-Costello O, West JB. Alveolar hypoxia increases gene expression of extracellular matrix proteins and platelet-derived growth factor–B in lung parenchyma. Am J Respir Crit Care Med 1998;158: 1920–1928.
68. Fuchs B, Sommer N, Dietrich A, et al. Redox signaling and reactive oxygen species in hypoxic pulmonary vasoconstriction. Respir Physiol Neurobiol 2010;174:282–291.
69. Csanyi G, Yao M, Rodriguez AI, et al. Thrombospondin-1 regulates blood flow via CD47 receptor-mediated activation of NADPH oxidase 1. Arterioscler Thromb Vasc Biol 2012; 32:2966–2973.
70. Bauer EM, Qin Y, Miller TW, et al. Thrombospondin-1 supports blood pressure by limiting eNOS activation and endothelialdependent vasorelaxation. Cardiovasc Res 2010;88:471–481.
71. Isenberg JS, Hyodo F, Matsumoto K, et al. Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide–mediated vascular smooth muscle relaxation. Blood 2007;109: 1945–1952.